Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis

Leukemia

Volumn 21, Issue 4, 2007, Pages 797-804

  Ramirez, J M ^a   Ocio, E M ^a,b   San Miguel, J F ^a,b   Pandiella, A ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEMETREXED;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

EID: 33947359103     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404599     Document Type: Article

References (21)

1. Dispenzieri A, Kyle RA. Multiple myeloma: Clinical features and indications for therapy. Best Pract Res Clin Haematol 2005; 18: 553-568.
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
3. Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium. Nat Rev Drug Discov 2004; 3: 825-826.
4. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123.
5. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C et al. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531.
6. Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C et al. Cellular pharmacology of MTA: A correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol 1999; 26: 48-54.
7. Gibbs D, Jackman A. Permetrexed disodium. Nat Rev Drug Discov 2005; 4 (Suppl): S16-S17.
8. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors. Oncologist 2001; 6: 363-373.
9. Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA. P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Cancer Res 2004; 64: 6296-6303.
10. Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J et al. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004; 10: 3562-3571.
11. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.
12. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999; 44: 105-110.
13. Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J et al. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999; 26: 55-62.
14. Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000; 6: 1016-1023.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
16. Hanna NH. Second-line chemotherapy for non-small-cell lung cancer: recent data with permetrexed. Clin Lung Cancer 2004; 5 (Suppl 2): S75-S79.
17. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004; 6: 439-444.
18. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789.
19. Cabrera N, Diaz-Rodriguez E, Becker E, Martin-Zanca D, Pandiella A. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment J Cell Biol 1996; 132: 427-436.
20. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-219.
21. Gartel AL, Radhakrishnan SK. Lost in transcription: P21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985.